top of page

Clinical Stage I

ARV-102 shows strong brain penetration, broad LRRK2 degradation, and good tolerability in healthy volunteers—supporting its advance into Phase 1 trials for Parkinson’s disease.

Written by Arvinas, Inc. Featuring commentary from Dr. Noah Berkowitz

April 4, 2025

bottom of page